Search
Faeth Therapeutics Ord Shs
FTHAdd to Watchlist
10.560USD
-11.490-52.11%
Market hours 11/09, 12:15（ET）
272.87MMarket Cap
0.00P/E TTM
FTH Analyst Recommendation Trends
In the current month, FTH has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. FTH average Analyst price target in the last month is 55.385.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
6
6
5
3
2
1
0
0
8
8
5
3
2
0
0
0
0
0
0
0
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14
14
10
6
5
2
1
1
Financial Forecasting
Based on analysts' estimates, FTH EPS is projected to reach -0.770 in FY2026Q4, following reported EPS of -0.789 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.62
-3.05
-0.79
-0.77
-0.74
Actual
-131.45
-2.84
-0.79
--
--
Surprise
-21101.79%
+6.94%
+0.16%
--
--
FAQs
How have Faeth Therapeutics Ord ShsFTH's recent earnings per share performed?
The market expectation was USD -0.79, while Faeth Therapeutics Ord ShsFTH's earnings per share (EPS) for the previous quarter was USD -2.84. EPS for the next quarter is expected at USD -0.77.
What is the analyst rating for Faeth Therapeutics Ord Shs?
Based on the ratings of Faeth Therapeutics Ord Shs's stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.